Enming Xing

Enming Xing

Auto-generated profile, based on publicly available information

Enming Xing

College of Pharmacy, The Ohio State University, Columbus, OH, 43210, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2025 in Chemical Science
Verified
Journal Article
Open access
PDF file
SWShen Wang
Shen Wang
TLTong Lin
Tong Lin
TPTianyi Peng
Tianyi Peng
EXEnming Xing
Enming Xing
SCSijie Chen
Sijie Chen
Xiaolin ChengXiaolin Cheng
Xiaolin Cheng
This work introduces Topology Molecular Type assignment (TopMT-GAN), a novel approach using Generative Adversarial Networks (GANs) for structure-based ligand design.

1 August 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SNShu Ning
Shu Ning
CACameron M. Armstrong
Cameron M. Armstrong
EXEnming Xing
Enming Xing
ALAmy Rose Leslie
Amy Rose Leslie
RGRichard Y. Gao
Richard Y. Gao
AGAllen Gao
Allen Gao
The development of resistance to current standard-of-care treatments, such as androgen receptor (AR) targeting therapies, remains a major challenge in the management of advanced prostate cancer. There is an urgent need for new therapeutic strategies targeting key resistant drivers, such as AR variants like AR-V7, and steroidogenic enzymes, such as aldo–keto reductase 1C3 (AKR1C3), to overcome drug resistance and improve outcomes for patients with advanced prostate cancer. Here, we have designed, synthesized, and characterized a novel class of LX compounds targeting both the AR/AR variants and AKR1C3 pathways. Molecular docking and in vitro studies demonstrated that LX compounds bind to the AKR1C3 active sites and inhibit AKR1C3 enzymatic activity. LX compounds were also shown to reduce AR/AR-V7 expression and to inhibit their target gene signaling. LX1 inhibited the conversion of androstenedione into testosterone in tumor-based ex vivo enzyme assays. In addition, LX1 inhibited the growth of cells resistant to antiandrogens including enzalutamide (Enza), abiraterone, apalutamide, and darolutamide in vitro. A synergistic effect was observed when LX1 was combined with antiandrogens and taxanes, indicating the potential for this combination in treating resistant prostate cancer. Treatment with LX1 significantly decreased tumor volume, serum PSA levels, as well as reduced intratumoral testosterone levels, without affecting mouse body weight. Furthermore, LX1 was found to overcome resistance to Enza treatment, and its combination with Enza further suppressed tumor growth in both the CWR22Rv1 xenograft and LuCaP35CR patient-derived xenograft models. Collectively, the dual effect of LX1 in reducing AR signaling and intratumoral testosterone, along with its synergy with standard therapies in resistant models, underscores its potential as a valuable treatment option for advanced prostate cancer. Significance: LX1 simultaneously targets androgen receptor variants and the steroidogenic enzyme AKR1C3, offering a promising approach to combat drug resistance and enhancing therapeutic efficacy in conjunction with standard treatments for advanced prostate cancer.

9 February 2026 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
HJHaowen Jiang
Haowen Jiang
AMAlessio Macorano
Alessio Macorano
EXEnming Xing
Enming Xing
MJMohamed Jedoui
Mohamed Jedoui
SMShabber Mohammed
Shabber Mohammed
PLPui Kai Li
Pui Kai Li
Niclosamide, an FDA-approved anthelmintic, functions as a mitochondrial uncoupler with promising anticancer potential, yet its efficacy remains limited, often ascribed to poor bioavailability. We identify a more fundamental constraintits narrow therapeutic window arising from a biphasic mechanism that promotes uncoupling at low doses but inhibits respiration at higher doses. To overcome this limitation, we synthesized 30 niclosamide analogs, systematically profiled their mitochondrial responses using Seahorse MitoTox assay, and developed QSAR models to uncover structural determinants of efficacy and toxicity. Niclosamide exhibited a narrow uncoupling range (0.5-1 μM) beyond which respiration was suppressed. Several analogs, including Nic-2, Nic-8, Nic-40, and Nic-43, sustained uncoupling for up to 9 h at concentrations up to 10 μM, with some showing improved signal modulation and reduced cytotoxicity. QSAR analysis revealed that substitution electronic properties and ring-specific hydrophobicity are related to the therapeutic index. These findings expand niclosamide's therapeutic window through rational scaffold tuning, enabling safer mitochondrial reprogramming strategies for cancer therapy.

4 November 2024
Verified
Other
Open access
PDF file
SNShu Ning
Shu Ning
CACameron M. Armstrong
Cameron M. Armstrong
EXEnming Xing
Enming Xing
ALAmy Rose Leslie
Amy Rose Leslie
RGRichard Y. Gao
Richard Y. Gao
AGAllen Gao
Allen Gao
Suppl. Figure 1-10, Table 1-2.

17 June 2026
Verified
Other
Open access
SNShu Ning
Shu Ning
CACameron M. Armstrong
Cameron M. Armstrong
EXEnming Xing
Enming Xing
ALAmy Rose Leslie
Amy Rose Leslie
RGRichard Y. Gao
Richard Y. Gao
AGAllen Gao
Allen Gao
Suppl. Figure 1-10, Table 1-2.

17 June 2026
Verified
Other
Open access
SNShu Ning
Shu Ning
CACameron M. Armstrong
Cameron M. Armstrong
EXEnming Xing
Enming Xing
ALAmy Rose Leslie
Amy Rose Leslie
RGRichard Y. Gao
Richard Y. Gao
AGAllen Gao
Allen Gao
The development of resistance to current standard-of-care treatments, such as androgen receptor (AR) targeting therapies, remains a major challenge in the management of advanced prostate cancer. There is an urgent need for new therapeutic strategies targeting key resistant drivers, such as AR variants like AR-V7, and steroidogenic enzymes, such as aldo–keto reductase 1C3 (AKR1C3), to overcome drug resistance and improve outcomes for patients with advanced prostate cancer. Here, we have designed, synthesized, and characterized a novel class of LX compounds targeting both the AR/AR variants and AKR1C3 pathways. Molecular docking and in vitro studies demonstrated that LX compounds bind to the AKR1C3 active sites and inhibit AKR1C3 enzymatic activity. LX compounds were also shown to reduce AR/AR-V7 expression and to inhibit their target gene signaling. LX1 inhibited the conversion of androstenedione into testosterone in tumor-based ex vivo enzyme assays. In addition, LX1 inhibited the growth of cells resistant to antiandrogens including enzalutamide (Enza), abiraterone, apalutamide, and darolutamide in vitro. A synergistic effect was observed when LX1 was combined with antiandrogens and taxanes, indicating the potential for this combination in treating resistant prostate cancer. Treatment with LX1 significantly decreased tumor volume, serum PSA levels, as well as reduced intratumoral testosterone levels, without affecting mouse body weight. Furthermore, LX1 was found to overcome resistance to Enza treatment, and its combination with Enza further suppressed tumor growth in both the CWR22Rv1 xenograft and LuCaP35CR patient-derived xenograft models. Collectively, the dual effect of LX1 in reducing AR signaling and intratumoral testosterone, along with its synergy with standard therapies in resistant models, underscores its potential as a valuable treatment option for advanced prostate cancer.Significance:LX1 simultaneously targets androgen receptor variants and the steroidogenic enzyme AKR1C3, offering a promising approach to combat drug resistance and enhancing therapeutic efficacy in conjunction with standard treatments for advanced prostate cancer.